LAUSR

Psoriasis is the most common chronic autoimmune disease. The pathophysiology, genetics, comorbidities, and biologic therapies of plaque psoriasis have seen the most rapid advances. Only a tiny percentage of the supplied dose reaches the target site in most situations (traditional dosage forms), while the balance is distributed throughout the body according to its physicochemical and biochemical properties. The current worker used nanotechnology to carry out study on the formulation and evaluation of nanoparticulate Berberine HCl loaded Chitosan coated sodium alginate nanoparticles. The Berberine HCl Nanoparticles were optimised using the Box-Behnken design. Particle size (68.82-275.78nm), zeta potential ((10.90)– (47.1 mv), percentage yield (80.75 percent - 96.21percent), percentage drug entrapment (50.95 -77.28percent), and percentage release in pH 7.4 phosphate buffer (60.848 - 95.869percent) were all found to be positive with Berberine HCl nanoparticles. Nanoparticles were found to be spherical in shape with rough surfaces, according to surface morphology (SEM). In a pH 7.4 phosphate buffer, an in-vitro drug release investigation on an optimised batch of Berberine HCl nanoparticles (BE-OPT) revealed 96.242percent (12 h) release. The release kinetic investigation with the optimised batch of Berberine HCl nanoparticles (BE-OPT) demonstrated that Higuchi's release kinetic model was followed. The chosen (optimised) nanoparticles were sealed in amber-coloured bottles with cotton plugs and caps. All were kept for six months at 40±2°C/75±5% RH and examined for their physical appearance and drug content at certain intervals.